Aclaris Therapeutics (ACRS) H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference summary

Lead candidate overview and scientific rationale

• ATI-052 is a bispecific antibody targeting TSLP and IL-4R, designed for inflammatory skin diseases like atopic dermatitis and asthma, with best-in-class potency and long retention time.

• The molecule achieves 100% inhibition of TSLP, IL-4, and IL-13 activity, showing synergy over existing monotherapies and greater potency than the combination of current market leaders.

• Clinical expectations include enhanced efficacy on IGA and EASI scores, with early and durable activity surpassing current standards.

Dosing, pharmacokinetics, and commercial potential

• ATI-052 demonstrates a half-life exceeding 40 days, supporting dosing intervals of up to three months, a significant improvement over current therapies.

• Three-month dosing is considered optimal for chronic inflammatory diseases, balancing efficacy, safety, and patient convenience.

• The molecule is being developed for delivery via prefilled syringes and needle pens, aligning with market expectations.

Safety profile and competitive differentiation

• No conjunctivitis observed in early studies, potentially due to the unique bispecific mechanism, which may also reduce other off-target effects.

• The construct’s design may offer safety advantages over both monotherapies and trispecific competitors, with ongoing studies to confirm these findings.